A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
Sign Up to like & getrecommendations! Published in 2022 at "Advances in Therapy"
DOI: 10.1007/s12325-021-02025-w
Abstract: A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler® device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS) therapy… read more here.
Keywords: development; ind gly; strategy; fixed dose ... See more keywords
Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa1075
Abstract: Introduction: Inhaled corticosteroid use is associated with risk of many adverse events (AEs), including pneumonia. A steroid-free regimen may offer safety benefits; hence, we conducted a post-hoc analysis of respiratory-related AEs in patients with moderate-to-very… read more here.
Keywords: safety; flame study; respiratory; ind gly ... See more keywords
Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa936
Abstract: Introduction: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in reducing the rate and risk of exacerbations 1 . Here, we determined the NNT for IND/GLY to prevent 1 COPD exacerbation,… read more here.
Keywords: flame study; nnt ind; prevent; exacerbation ... See more keywords
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa939
Abstract: Introduction/Aim: Results from the recent one-year FLAME study demonstrated superior efficacy of IND/GLY over SFC in reducing the annual rate of moderate and severe exacerbations in COPD patients with moderate to very severe airflow limitation… read more here.
Keywords: ind; copd patients; sfc swedish; ind gly ... See more keywords
Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy in patients with asthma: REACH study design
Sign Up to like & getrecommendations! Published in 2022 at "ERJ Open Research"
DOI: 10.1183/23120541.00452-2022
Abstract: Cough is a major symptom in patients with asthma and poses a significant burden compared with other asthma symptoms. However, there are no approved treatments in Japan, developed to specifically treat cough in patients with… read more here.
Keywords: reach; cough; ics laba; patients asthma ... See more keywords
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s392975
Abstract: Background Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or… read more here.
Keywords: flu sal; gly ind; patients asthma; sal ... See more keywords